Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport
申请人:Wyeth
公开号:US20030022930A1
公开(公告)日:2003-01-30
This invention provides compounds of the formula:
1
wherein X is (CH
2
)
n
, O, S, SO, SO
2
or CR
1
R
2
; n is 1 or 2; R
1
and R
2
are H, halogen, hydroxy, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or R
1
and R
2
, taken together form cycloalkyl of 3 to 6 carbon atoms, an alkylidene of up to 6 carbon atoms or a carbonyl; R
3
, R
4
and R
5
are H or alkyl of 1 to 6 carbon atoms; Z is H, alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms or alkoxycarbonyl of 2 to 7 carbon atoms; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods for their use in treating or preventing characterized by glutamate hypofunction, including schizophrenia, schizoaffective disorder and schizophreniform disorder, and for the treatment of cognitive deficits due to aging, stroke, Alzheimer's disease or other neurodegenerative diseases.
本发明提供了公式1的化合物:其中X为(CH2)n,O,S,SO,SO2或CR1R2;n为1或2;R1和R2为H,卤素,羟基,1至6个碳原子的烷基,1至6个碳原子的烷氧基,或者R1和R2共同形成3至6个碳原子的环烷基,最多6个碳原子的烷基或者羰基;R3、R4和R5为H或者1至6个碳原子的烷基;Z为H,1至6个碳原子的烷基,1至6个碳原子的烷酰基或者2至7个碳原子的烷氧羰基;或其药学上可接受的盐,以及其在治疗或预防谷氨酸低功能性疾病(包括精神分裂症、情感性精神障碍和类精神分裂障碍)以及治疗因衰老、中风、阿尔茨海默病或其他神经退行性疾病所致的认知障碍方面的使用的制药组合物和方法。